SG11201707182WA - Immunomodulatory fusion proteins and uses thereof - Google Patents
Immunomodulatory fusion proteins and uses thereofInfo
- Publication number
- SG11201707182WA SG11201707182WA SG11201707182WA SG11201707182WA SG11201707182WA SG 11201707182W A SG11201707182W A SG 11201707182WA SG 11201707182W A SG11201707182W A SG 11201707182WA SG 11201707182W A SG11201707182W A SG 11201707182WA SG 11201707182W A SG11201707182W A SG 11201707182WA
- Authority
- SG
- Singapore
- Prior art keywords
- fusion proteins
- immunomodulatory fusion
- immunomodulatory
- proteins
- fusion
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 230000002519 immonomodulatory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70507—CD2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562128979P | 2015-03-05 | 2015-03-05 | |
PCT/US2016/021064 WO2016141357A1 (en) | 2015-03-05 | 2016-03-04 | Immunomodulatory fusion proteins and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201707182WA true SG11201707182WA (en) | 2017-10-30 |
Family
ID=55587371
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201707182WA SG11201707182WA (en) | 2015-03-05 | 2016-03-04 | Immunomodulatory fusion proteins and uses thereof |
SG10201908203S SG10201908203SA (en) | 2015-03-05 | 2016-03-04 | Immunomodulatory Fusion Proteins And Uses Thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201908203S SG10201908203SA (en) | 2015-03-05 | 2016-03-04 | Immunomodulatory Fusion Proteins And Uses Thereof |
Country Status (16)
Country | Link |
---|---|
US (2) | US20180044404A1 (zh) |
EP (1) | EP3265481B1 (zh) |
JP (3) | JP6917896B2 (zh) |
KR (1) | KR20170120701A (zh) |
CN (1) | CN107531805A (zh) |
AU (3) | AU2016226022B2 (zh) |
BR (1) | BR112017018919A8 (zh) |
CA (2) | CA2978186A1 (zh) |
HK (1) | HK1246317A1 (zh) |
IL (1) | IL254165B (zh) |
MX (4) | MX2017011201A (zh) |
MY (2) | MY196588A (zh) |
RU (1) | RU2755227C2 (zh) |
SA (1) | SA517382216B1 (zh) |
SG (2) | SG11201707182WA (zh) |
WO (1) | WO2016141357A1 (zh) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
CN106459914B (zh) | 2014-05-15 | 2020-11-06 | 新加坡国立大学 | 经修饰的自然杀伤细胞及其用途 |
US20180044404A1 (en) | 2015-03-05 | 2018-02-15 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
CA2986254A1 (en) | 2015-05-18 | 2016-11-24 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2017112944A1 (en) | 2015-12-23 | 2017-06-29 | Fred Hutchinson Cancer Research Center | High affinity t cell receptors and uses thereof |
EP4286522A3 (en) * | 2016-03-23 | 2024-02-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
KR20190019068A (ko) | 2016-05-18 | 2019-02-26 | 큐 바이오파마, 인크. | T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법 |
TWI780057B (zh) | 2016-07-14 | 2022-10-11 | 美商必治妥美雅史谷比公司 | 針對tim3之抗體及其用途 |
WO2018009972A1 (en) * | 2016-07-14 | 2018-01-18 | Peter Maccallum Cancer Institute | Chimeric antigen receptor modified t cells |
WO2018098365A2 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
US20200095547A1 (en) * | 2016-12-02 | 2020-03-26 | Darya ALIZADEH | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors |
AU2017382243A1 (en) * | 2016-12-22 | 2019-05-02 | Windmil Therapeutics, Inc. | Compositions and methods for modulating the immune system |
EP3558339B1 (en) | 2016-12-22 | 2024-01-24 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE |
IL269000B2 (en) | 2017-03-15 | 2024-06-01 | Cue Biopharma Inc | Methods for modulating an immune response |
CA3055784A1 (en) * | 2017-03-17 | 2018-09-20 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
MX2019011514A (es) | 2017-03-27 | 2020-01-27 | Nat Univ Singapore | Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales. |
US11896616B2 (en) | 2017-03-27 | 2024-02-13 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
EP3661965A4 (en) | 2017-08-02 | 2022-07-13 | Phanes Therapeutics, Inc. | ANTI-CD47 ANTIBODIES AND USES THEREOF |
US10960071B2 (en) | 2017-08-07 | 2021-03-30 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
KR20220124817A (ko) | 2017-08-07 | 2022-09-14 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 안전한 세포 치료제를 생성하기 위한 플랫폼 |
EP3678677A4 (en) * | 2017-09-07 | 2021-06-16 | Cue Biopharma, Inc. | ANTIGEN PRESENTATION POLYPEPTIDES AND THEIR METHODS OF USE |
WO2019055862A1 (en) | 2017-09-14 | 2019-03-21 | Fred Hutchinson Cancer Research Center | HIGH AFFINITY T CELL RECEPTORS AND USES THEREOF |
WO2019090355A1 (en) * | 2017-11-06 | 2019-05-09 | Children's National Medical Center | Cells expressing antibodies and methods of treatment using the same |
CN111542595B (zh) * | 2017-11-10 | 2023-05-09 | 北京卡替医疗技术有限公司 | 经修饰的免疫细胞及其用途 |
WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
AU2019290192A1 (en) * | 2018-06-21 | 2021-01-07 | Shattuck Labs, Inc. | Heterodimeric proteins and uses thereof |
KR102261407B1 (ko) * | 2018-10-10 | 2021-06-08 | 한국화학연구원 | Hvem을 표적으로 하는 키메라 항원 수용체 |
TW202039542A (zh) | 2018-12-19 | 2020-11-01 | 美商庫爾生物製藥有限公司 | 多聚體t細胞調節多肽及其使用方法 |
GB201900858D0 (en) * | 2019-01-22 | 2019-03-13 | Price Nicola Kaye | Receptors providing targeted costimulation for adoptive cell therapy |
WO2020180882A1 (en) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
CA3132845A1 (en) | 2019-03-11 | 2020-09-17 | Fred Hutchinson Cancer Research Center | High avidity wt1 t cell receptors and uses thereof |
WO2020190771A1 (en) * | 2019-03-15 | 2020-09-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy |
US20220143089A1 (en) * | 2019-03-21 | 2022-05-12 | Onk Therapeutics Limited | Modified immune effector cells with increased resistance to cell death |
CN114007642A (zh) | 2019-04-30 | 2022-02-01 | 森迪生物科学公司 | 嵌合受体及其使用方法 |
KR20220106803A (ko) * | 2019-11-27 | 2022-07-29 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Nk 세포에 대한 대규모 조합형 car 형질도입 및 crispr 유전자 편집 |
US20230000918A1 (en) * | 2019-11-29 | 2023-01-05 | Suzhou Nova Therapeutics Co. Ltd | Chimeric antigen receptors, compositions and applications thereof |
EP4132963A2 (en) * | 2020-04-09 | 2023-02-15 | Autolus Limited | Cell |
GB202101491D0 (en) * | 2021-02-03 | 2021-03-17 | Autolus Ltd | Molecule |
WO2021205175A1 (en) * | 2020-04-09 | 2021-10-14 | Autolus Limited | Molecule |
KR20230009872A (ko) | 2020-05-12 | 2023-01-17 | 큐 바이오파마, 인크. | 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법 |
JP2023527194A (ja) * | 2020-05-22 | 2023-06-27 | 重▲慶▼精准生物技▲術▼有限公司 | 腫瘍微小環境を逆転させる融合タンパク質及びその使用 |
US20230295564A1 (en) * | 2020-07-23 | 2023-09-21 | Emory University | Galectin-9 Specific Binding Agents for Use in Treating Cancer |
WO2022246041A2 (en) * | 2021-05-20 | 2022-11-24 | Achelois Biopharma, Inc. | Compositions and methods for multivalent surface display on enveloped particles |
CN117813106A (zh) * | 2021-05-20 | 2024-04-02 | 阿奇洛伊斯生物制药公司 | 免疫检查点多价颗粒组合物和使用方法 |
US11945876B2 (en) | 2021-06-16 | 2024-04-02 | Instil Bio (Uk) Limited | Receptors providing targeted costimulation for adoptive cell therapy |
EP4370213A1 (en) | 2021-07-16 | 2024-05-22 | Instil Bio (Uk) Limited | Chimeric molecules providing targeted costimulation for adoptive cell therapy |
CN113621077B (zh) * | 2021-09-02 | 2023-01-31 | 山东大学 | 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞 |
WO2023150801A2 (en) * | 2022-02-07 | 2023-08-10 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
JP4137997B2 (ja) | 1994-01-11 | 2008-08-20 | ダイアックス コープ. | クニッツドメインから誘導されたヒトプラスミンの阻害剤 |
WO1996013584A1 (en) | 1994-11-01 | 1996-05-09 | Targeted Genetics Corporation | Chimeric receptors for the generation of selectively-activatable th-independent cytotoxic t cells |
US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
DK1791865T3 (da) | 2004-06-29 | 2010-11-01 | Immunocore Ltd | Celler der udtrykker en modificeret T-cellerecptor |
DE602006003695D1 (de) | 2005-01-05 | 2009-01-02 | F Star Biotech Forsch & Entw | Synthetische Immunoglobulindomänen mit in Regionen des Moleküls, die sich von den die Komplementarität bestimmenden Bereichen unterscheiden, modifizierten Bindeeigenschaften |
GB0504767D0 (en) | 2005-03-08 | 2005-04-13 | Ares Trading Sa | Lipocalin protein |
EP1829895A1 (en) | 2006-03-03 | 2007-09-05 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
US8119772B2 (en) | 2006-09-29 | 2012-02-21 | California Institute Of Technology | MART-1 T cell receptors |
JP2010539915A (ja) | 2007-09-24 | 2010-12-24 | ユニバーシティ・オブ・チューリッヒ | 設計されたアルマジロリピートタンパク質 |
WO2012012695A2 (en) * | 2010-07-23 | 2012-01-26 | Fred Hutchinson Cancer Research Center | A method for the treatment of obesity |
WO2012042480A1 (en) | 2010-09-28 | 2012-04-05 | Kahr Medical Ltd. | Compositions and methods for treatment of hematological malignancies |
BR122021026169B1 (pt) * | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
AU2012230780B2 (en) * | 2011-03-23 | 2016-10-27 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
CN107164330A (zh) | 2011-04-08 | 2017-09-15 | 贝勒医学院 | 使用嵌合细胞因子受体逆转肿瘤微环境的影响 |
EP2736540B1 (en) | 2011-07-29 | 2019-03-13 | The Trustees Of The University Of Pennsylvania | Switch costimulatory receptors |
KR101471647B1 (ko) * | 2011-10-26 | 2014-12-11 | 국립암센터 | 변이 ctla4 유전자 이입 t 세포 및 이를 포함하는 항암 면역치료용 조성물 |
EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
AU2013371826A1 (en) | 2013-01-01 | 2015-08-13 | Kahr Medical Ltd. | Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof |
US20160008399A1 (en) * | 2013-01-14 | 2016-01-14 | Fred Hutchinson Cancer Research Center | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse |
CN103965361B (zh) | 2013-02-06 | 2018-10-30 | 上海细胞治疗工程技术研究中心集团有限公司 | 一种t细胞信号的嵌合分子转换器及其用途 |
CN105452287A (zh) | 2013-04-17 | 2016-03-30 | 贝勒医学院 | 免疫抑制性TGF-β信号转换器 |
CA2955154C (en) | 2014-07-21 | 2023-10-31 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
MY181834A (en) | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
AR101829A1 (es) | 2014-07-21 | 2017-01-18 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1 |
WO2016022400A1 (en) * | 2014-08-04 | 2016-02-11 | Fred Hutchinson Cancer Research Center | T cell immunotherapy specific for wt-1 |
HUE046661T2 (hu) * | 2014-08-15 | 2020-03-30 | Merck Patent Gmbh | SIRP-alfa immunglobulin fúziós proteinek |
ES2744910T3 (es) | 2014-12-24 | 2020-02-26 | Ucl Business Ltd | Célula |
JP6734283B2 (ja) * | 2015-01-21 | 2020-08-05 | フレッド ハッチンソン キャンサー リサーチ センター | 遺伝子治療用ポイントオブケア及び/又はポータブルプラットフォーム |
US20180044404A1 (en) | 2015-03-05 | 2018-02-15 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
CN115927474A (zh) | 2015-06-19 | 2023-04-07 | 塞巴斯蒂安·科博尔德 | Pd-1-cd28融合蛋白及其在医学中的用途 |
EP3708588A1 (en) | 2015-11-27 | 2020-09-16 | Cartherics Pty. Ltd. | Genetically modified cells and uses thereof |
WO2017112944A1 (en) * | 2015-12-23 | 2017-06-29 | Fred Hutchinson Cancer Research Center | High affinity t cell receptors and uses thereof |
US10188749B2 (en) * | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
US20190127435A1 (en) * | 2016-04-20 | 2019-05-02 | Fred Hutchinson Cancer Research Center | Immunomodulatory il2r fusion proteins and uses thereof |
CA3055784A1 (en) | 2017-03-17 | 2018-09-20 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
WO2019061012A1 (zh) | 2017-09-26 | 2019-04-04 | 南京凯地生物科技有限公司 | 靶向cd47的特异性嵌合抗原受体t细胞的制备及其应用 |
CN110330567B (zh) | 2019-07-02 | 2020-11-06 | 南京凯地生物科技有限公司 | 双特异性嵌合抗原受体t细胞,其制备方法和应用 |
-
2016
- 2016-03-04 US US15/555,951 patent/US20180044404A1/en not_active Abandoned
- 2016-03-04 WO PCT/US2016/021064 patent/WO2016141357A1/en active Application Filing
- 2016-03-04 SG SG11201707182WA patent/SG11201707182WA/en unknown
- 2016-03-04 MX MX2017011201A patent/MX2017011201A/es unknown
- 2016-03-04 EP EP16711081.6A patent/EP3265481B1/en active Active
- 2016-03-04 MY MYPI2021007596A patent/MY196588A/en unknown
- 2016-03-04 CA CA2978186A patent/CA2978186A1/en active Pending
- 2016-03-04 BR BR112017018919A patent/BR112017018919A8/pt active Search and Examination
- 2016-03-04 RU RU2017133637A patent/RU2755227C2/ru active
- 2016-03-04 MY MYPI2017001281A patent/MY189195A/en unknown
- 2016-03-04 KR KR1020177027794A patent/KR20170120701A/ko not_active Application Discontinuation
- 2016-03-04 CN CN201680023758.4A patent/CN107531805A/zh active Pending
- 2016-03-04 JP JP2017546715A patent/JP6917896B2/ja active Active
- 2016-03-04 SG SG10201908203S patent/SG10201908203SA/en unknown
- 2016-03-04 CA CA3177938A patent/CA3177938A1/en active Pending
- 2016-03-04 AU AU2016226022A patent/AU2016226022B2/en active Active
-
2017
- 2017-08-27 IL IL254165A patent/IL254165B/en unknown
- 2017-08-30 SA SA517382216A patent/SA517382216B1/ar unknown
- 2017-08-31 MX MX2022006002A patent/MX2022006002A/es unknown
- 2017-08-31 MX MX2022006006A patent/MX2022006006A/es unknown
- 2017-08-31 MX MX2022006004A patent/MX2022006004A/es unknown
-
2018
- 2018-05-03 HK HK18105732.2A patent/HK1246317A1/zh unknown
-
2020
- 2020-05-01 JP JP2020081118A patent/JP7026161B2/ja active Active
- 2020-09-30 AU AU2020244495A patent/AU2020244495B2/en active Active
-
2021
- 2021-02-03 US US17/166,903 patent/US12012443B2/en active Active
- 2021-09-15 JP JP2021150184A patent/JP7441201B2/ja active Active
-
2022
- 2022-11-16 AU AU2022271411A patent/AU2022271411A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1246317A1 (zh) | 免疫調節融合蛋白及其用途 | |
IL265657A (en) | Immunomodulatory fusion proteins | |
HK1250043A1 (zh) | Gitrl融合蛋白及其用途 | |
HRP20190028T1 (hr) | Interleukin-2 fuzijski proteini i njihove primjene | |
IL262366B2 (en) | Immunomodulatory proteins and CD80 variants and their uses | |
ZA201808284B (en) | Gdf15 fusion proteins and uses thereof | |
HK1244019A1 (zh) | 融合蛋白 | |
IL249327A0 (en) | mic-1 fusion proteins and their uses | |
GB201509062D0 (en) | OX40L fusion proteins and uses thereof | |
GB2570063B (en) | Fusion protein and applications thereof | |
IL273626A (en) | Immunomodulatory fusion proteins | |
GB2543713B (en) | Polymeric proteins and uses thereof | |
EP3237452A4 (en) | Fusion proteins and methods thereof | |
GB201602850D0 (en) | Fusion proteins | |
HK1251456A1 (zh) | 免疫球蛋白融合蛋白及其用途 | |
GB201617925D0 (en) | Proteins and uses |